BSE filing, NSE: KABRADG. Summary written from the filing by ALFA Finder's alert engine.
Kabra Drugs Ltd: key numbers
- Share price
- ₹16.26
- Market cap
- ₹38.55 Cr
- Revenue (annual)
- ₹92.74 Cr
- Net profit (annual)
- ₹4.96 Cr
- P/E (TTM)
- 5.1×Sector 46.1×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kabra Drugs Ltd
All →Kabra Drugs Other Announcement
The company has filed its quarterly shareholding pattern for the period ending September 30, 2026. The document discloses the distribution of shareholding among various categories of investors.
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited conducted its 37th Annual General Meeting on September 30, 2026. Shareholders transacted business including the adoption of financial statements and director appointments.
Kabra Drugs Annual Report
Aanjaay Industries Ltd has submitted its Annual Report for FY 2025-2026 and issued notice for its 37th AGM scheduled for 30th September 2026.
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited announced book closure dates from September 24th to September 30th, 2026, for its Annual General Meeting scheduled for September 30th, 2026.
Kabra Drugs Other Announcement
Aanjaay Industries Limited has shifted its registered office from Indore, Madhya Pradesh, to Chennai, Tamil Nadu, effective August 28, 2026.
Kabra Drugs Board Meeting Date
Aanjaay Industries Limited has scheduled a board meeting for September 2, 2026. The agenda includes approving the Director's Report and fixing details for the upcoming AGM.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.